|
|
Article: ORADUR(TM) Technology Milestone: New ORADUR-based Investigational Drug Candidate Commences Phase I Clinical Program.
- Article from:
- PR Newswire
- Article date:
- August 2, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CUPERTINO, Calif., Aug. 2 /PRNewswire-FirstCall/ -- DURECT Corporation reported today the initiation of a Phase I clinical trial for a new ORADUR-based opioid drug candidate. This new drug candidate is the second ORADUR-based opioid drug to undergo clinical testing by King Pharmaceuticals, Inc., the company which will be commercializing the drug candidate, if approved, and Pain Therapeutics, Inc., DURECT's licensee of the rights to the drug candidate and other ORADUR-based products incorporating oxycodone and three other opioid compounds. The first drug candidate under development by Pain Therapeutics and King Pharmaceuticals, Remoxy (ORADUR-based oxycodone), is ...
Related newspaper, magazine, and journal articles:
|
|
Article: King Pharmaceuticals and Pain ...
PR Newswire;
November 10, 2005 ;
700+ words
... ... PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. announced today it ... a strategic alliance with Pain Therapeutics, Inc. to develop and commercialize ... chief executive officer of King Pharmaceuticals, stated, "This alliance ...
|
|